Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

November 19, 2025 - Vancouver, British Columbia , Canada - Neurothera Labs Inc. (TSXV: NTLX) ("**Neurothera**" or the "**Company**"), a clinical-stage biotech company and an wholly-own subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.

The patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine Inc. This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.

This new filing further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed under the partnership, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.

About Neurothera Labs Inc.

Neurothera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty IR Manager

Neurothera Labs Inc.
Telephone: 972-3-7617108
Email: michal@efraty.com

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding its growing intellectual property portfolio, its mission to develop novel, science-backed solutions for some of the world's most challenging mental health conditions and advancing MEAI-based treatments toward clinical development. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning future results *or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Additional information identifying risks and uncertainties are contained in the filings by the Company with the Canadian securities regulators, which filings are available at www.sedarplus.ca.*